EP
VNDA icon

Essential Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Essential Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.2K Sell
2,809
-433
-13% -$2.83K 0.01% 968
2026
Q1 		$22.4K Buy
3,242
+454
+16% +$3.5K 0.01% 883
2025
Q4 		$24.6K Sell
2,788
-1,024
-27% -$5.64K 0.01% 831
2025
Q3 		$19K Buy
3,812
+3,345
+716% +$15.5K 0.01% 909
2025
Q2 		$2.2K Buy
+467
New +$2.04K ﹤0.01% 1286

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's VNDA Position: Q2 2026 in Review

Essential Partners reduced its Vanda Pharmaceuticals (VNDA) stake by 13% in Q2 2026, selling an estimated $2.83K and leaving 2,809 shares worth $17.2K. The position accounts for 0.01% of the portfolio, ranked #968.

Essential Partners first reported a position in VNDA in Q2 2025 and has held it in 5 quarters since. The position peaked at $24.6K in Q4 2025. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Essential Partners held 2,809 shares of Vanda Pharmaceuticals worth $17.2K as of Q2 2026.
  • Essential Partners sold 433 Vanda Pharmaceuticals shares in Q2 2026, an estimated $2.83K.
  • Vanda Pharmaceuticals made up 0.01% of Essential Partners's portfolio in Q2 2026, its #968 holding.
  • Essential Partners first reported a position in Vanda Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Vanda Pharmaceuticals position peaked at $24.6K in Q4 2025.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.